(Q36611045)

15 August 2017

1 reference

19 September 2019

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials (English)

1 reference

biomedical investigative technique

15 August 2017

1 reference

19 September 2019

S Marchetti

1

1 reference

15 August 2017

J H M Schellens

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

28 August 2007

1 reference

British Journal of Cancer

15 August 2017

3 September 2007

1 reference

19 September 2019

2 references

15 August 2017

19 September 2019

97

1 reference

15 August 2017

5

1 reference

15 August 2017

577-581

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603925

15 August 2017

0 references

cites work

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Improved early clinical development through human microdosing studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Can the pharmaceutical industry reduce attrition rates?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

The price of innovation: new estimates of drug development costs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

The value of improving the productivity of the drug development process: faster times and better decisions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Clinical trial design for target-based therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

PET for in vivo pharmacokinetic and pharmacodynamic measurements

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Combinatorial chemistry in cancer drug development.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Compressing drug development timelines in oncology using phase '0' trials.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360360

Risks in new drug development: approval success rates for investigational drugs

20 September 2018

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Less is more: the human microdosing concept

1 reference

12 December 2020

Slow start to phase 0 as researchers debate value

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603925

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

PubMed publication ID

17726450

1 reference